VBI Vaccines Inc. announced PreHevbrio is now available in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. PreHevbrio was approved by the U.S. Food and Drug Administration on November 30, 2021, and is the only approved 3-antigen HBV vaccine for adults. VBI is working with a network of wholesalers, distributors, group purchasing organizations, and federal accounts to enable broad access to PreHevbrio, and the Company expects to further build out this network in the coming weeks.

The Wholesale Acquisition Cost for PreHevbrio has been set at $64.75 per dose. In July 2021, the American Medical Association established a unique Current Procedural Terminology code for a 3-antigen Hepatitis B vaccine. This is the code PreHevbrio will be reported under and it differentiates PreHevbrio from other approved single-antigen HBV vaccines.

Many insurance plans and institutions also require recommendation from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices in order to provide reimbursement coverage. Following the February 2022 ACIP meeting, PreHevbrio was added to the list of ACIP-recommended products for prophylactic adult vaccination against HBV infection without the need for a formal vote. Additionally, VBI, in partnership with Syneos Health, has now deployed a field team of nearly 80 individuals devoted to PreHevbrio, including more than 50 vaccine sales specialists.

U.S. Indication: PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older.